Rift Valley fever virus: An unrecognized emerging threat?

Human Vaccines

Volumn 6, Issue 7, 2010, Pages 597-601

  Mandell, Robert B ^a   Flick, Ramon ^a  

^a BioProtection Systems Corporation   (United States)

Author keywords

Biothreat; Bunyavirus; Emerging; Livestock; Rift valley fever virus; Threat; Vaccines

Indexed keywords

RIFT VALLEY FEVER VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

BLINDNESS; DIAGNOSTIC TEST; DISEASE SEVERITY; ENCEPHALITIS; HEALTH CARE SYSTEM; HEPATITIS; HUMAN; INFECTION CONTROL; LIVESTOCK; MORTALITY; NOTE; RETINITIS; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; RISK ASSESSMENT; SEVERE ACUTE RESPIRATORY SYNDROME; SOCIETY; VACCINATION; VETERINARY MEDICINE; VIRUS HEMORRHAGIC FEVER; VIRUS TRANSMISSION;

EID: 77957009417     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.7.11761     Document Type: Note

References (38)

1. Weaver SC, Reisen WK. Present and future arboviral threats. Antiviral Res 2010; 85:328-45.
2. Elliott RM. The Bunyaviridae. New York and London: Plenum Press 1996.
3. Schmaljohn CS, Nichol ST. Bunyaviridae. In: DMK, ed. Field's Virology. Philadelphia: Lippincott Williams & Wilkins 2006; 1741-89.
4. Lee J-W, McKibbin WJ. Globalization and Disease: The Case of SARS. Asian Economic Papers 2004; 3:113-31.
5. Naylor CD. The complex world of prescribing behavior. JAMA 2004; 291:104-6.
6. Baric RS. SARS-CoV: lessons for global health. Virus Res 2008; 133:1-3.
7. Flick R, Bouloy M. Rift Valley fever virus. Curr Mol Med 2005; 5:827-34.
8. Bouloy M, Flick R. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res 2009; 84:101-18.
9. Gerdes GH. Rift Valley fever. Rev Sci Tech 2004; 23:613-23.
10. Gerdes GH. Rift valley fever. Vet Clin North Am Food Anim Pract 2002; 18:549-55.
11. Ikegami T, Makino S. Rift Valley fever vaccines. Vaccine 2009; 27:D69-D72.
12. Bird BH, Ksiazek TG, Nichol ST, MacLachlan NJ. Rift Valley fever virus. J Am Vet Med Assoc 2009; 234:883-93.
13. Hunter P, Erasmus BJ, Vorster JH. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res 2002; 69:95-8. (Pubitemid 34983797)
14. Bettinger GE, Peters CJ, Pittman P, Morrill JC, Ranadive M, Kormann RN, et al. Rift Valley Fever MP-12 Vaccine: A University, Government, & Industry Collaborative Development. Rift Valley Fever Workshop. Dokki, Giza, Cairo, Egypt 2009.
15. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, Smith J, et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995; 53:405-11.
16. Bird BH, Albarino CG, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 2008; 82:2681-91.
17. Grgacic E, Anderson D. Virus-like particles; passport to immune recognition. Methods 2006; 40:60-5. (Pubitemid 44415499)
18. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007; 18:537-45.
19. . Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, Holbrook MR, et al. A replicationincompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 2010; 397:187-98.
20. de Boer SM, Kortekaas J, Antonis AF, Kant J, van Oploo JL, Rottier PJ, et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 2010.
21. Hayes CG. West Nile virus: Uganda, 1937 to New York City. Annals of the New York Academy of Sciences 1999; 951:25-37.
22. Sardelis MR, Turell MJ, Dohm DJ, O'Guinn ML. Vector competence of selected North American Culex and Coquillettidia mosquitoes for West Nile virus. Emerg Infect Dis 2001; 7:1018-22.
23. Fontenille D, Traore-Lamizana M, Diallo M, Thonnon J, Digoutte JP, Zeller HG. New vectors of Rift Valley fever in West Africa. Emerg Infect Dis 1998; 4:289-93.
24. Moutailler S, Krida G, Schaffner F, Vazeille M, Failloux AB. Potential vectors of Rift Valley fever virus in the Mediterranean region. Vector Borne Zoonotic Dis 2008; 8:749-53.
25. Turell MJ, Kay BH. Susceptibility of selected strains of Australian mosquitoes (Diptera: Culicidae) to Rift Valley fever virus. J Med Entomol 1998; 35:132-5.
26. Turell MJ, Perkins PV. Transmission of Rift Valley fever virus by the sand fly, Phlebotomus duboscqi (Diptera: Psychodidae). Am J Trop Med Hyg 1990; 42:185-8.
27. Turell MJ, Dohm DJ, Mores CN, Terracina L, Wallette DL Jr, Hribar LJ, et al. Potential for North American mosquitoes to transmit Rift Valley fever virus. J Am Mosq Control Assoc 2008; 24:502-7.
28. Easterday BC. Rift valley fever. Adv Vet Sci 1965; 10:65-127.
29. USDA A. Part II. 7 CFR Part 331 and 9 CFR Part 212; Agricultural Bioterrorism Protection Act of 2002; possession, use and transfer of biological agents and toxins; final rule. Federal Register 2005; 13241-92.
30. HHS. Department of Health and Human Services. Possession, Use and Transfer of Biological Agents and Toxins, 42 CFR parts 72 and 73. 2005.
31. OIE. World Organization for Animal Health - Terrestrial Animal Health Code; Rift Valley Fever 2009; 8:11.
32. EFSA. The Risk of a Rift Valley Fever Incursion and its Persistence within the Community. EFSA Journal 2005; 238:1-128.
33. Kasari TR, Carr DA, Lynn TV, Weaver JT. Evaluation of pathways for release of Rift Valley fever virus into domestic ruminant livestock, ruminant wildlife and human populations in the continental United States. J Am Vet Med Assoc 2008; 232:514-29.
34. Britch SC, Linthicum KJ. Rift Valley Fever Working Group. Developing a research agenda and a comprehensive national prevention and response plan for Rift Valley fever in the United States. Aug 2007. Available from http://www.cdc.gov/EID/ content/13/8/e1.htm. Emerging Infectious Diseases [serial on the Internet].
35. Clements AC, Pfeiffer DU. Emerging viral zoonoses: frameworks for spatial and spatiotemporal risk assessment and resource planning. Vet J 2009; 182:21-30.
36. Goris N, Vandenbussche F, De Clercq K. Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock. Antiviral Res 2008; 78:170-8.
37. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare. A historical perspective. JAMA 1997; 278:412-7.
38. Graham R, Talent J. World at Risk: The Report of the Commission on the Prevention of WMD Proliferation and Terrorism. New York: Vintage Books 2008.